Araci Rondon

Araci Rondon is a postdoctoral researcher at the Einthoven Laboratory for Vascular and Regenerative Medicine, Div. of Thrombosis and Hemostasis, LUMC. Her research focuses on organ-on-a-chip technology, extracellular vesicles, Tissue Factor, 3D cellular models, cancer-associated thrombosis and thrombosis in the older population.

During her Ph.D. (2012-2017) at the Federal University of Rio de Janeiro (UFRJ, Brazil), she evaluated the influence of blood clotting proteins in tumor progression. She studied whether Tissue Factor (TF), the main activator of blood coagulation, is involved in Extracellular Vesicles (EVs) release (Rondon, et al., 2018). Her project showed that TF directs the secretion of EVs and described the pathways involved. During her Ph.D., she was awarded a grant from the Brazilian government (Science Without Borders, National Council for Scientific and Technological, CNPq) to work with Prof. Dr. Henri Versteeg, LUMC, The Netherlands (December 2013-November 2014).

Since January 2018, she has returned to LUMC. In November 2018, she got an ISTH/EHA fellowship award to study the release of TF-positive EVs from 2D and 3D tumor-stromal models for two months (April and May 2019) at the laboratory of Dr. Camille Ettelaie (Department of Biomedical Sciences, University of Hull, Kingston upon Hull). In 2019, dr. Araci Rondon and Prof. Henri Versteeg in collaboration with Mimetas B.V., the world leader in the organ-on-a-chip field, were awarded with a grant from Health Holland to develop animal-free methods to study thrombosis in cancer patients, and in 2020 they were awarded with a grant Health~Holland Project Recovery during the COVID-19 crisis.

In December 2022, dr. Araci Rondon, Prof. Henri Versteeg and collaborators from LUMC were awarded with a grant from Trombosestichting to study “Why are older individuals at higher risk of thrombosis?”.

Follow me on Twitter